Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN - Nasdaq - US52490G1022 - ADR - Currency: USD

34.28  +0.04 (+0.12%)

After market: 34.85 +0.57 (+1.66%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LEGN. LEGN was compared to 568 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEGN has reported negative net income.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
LEGN had a negative operating cash flow in each of the past 5 years.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

The Return On Assets of LEGN (-10.60%) is better than 86.80% of its industry peers.
With an excellent Return On Equity value of -17.01%, LEGN belongs to the best of the industry, outperforming 88.03% of the companies in the same industry.
Industry RankSector Rank
ROA -10.6%
ROE -17.01%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

LEGN has a better Gross Margin (62.60%) than 78.70% of its industry peers.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LEGN has an Altman-Z score of 7.35. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
LEGN has a Altman-Z score of 7.35. This is amongst the best in the industry. LEGN outperforms 84.86% of its industry peers.
A Debt/Equity ratio of 0.33 indicates that LEGN is not too dependend on debt financing.
LEGN has a Debt to Equity ratio of 0.33. This is in the lower half of the industry: LEGN underperforms 72.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 7.35
ROIC/WACCN/A
WACC9.94%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.62 indicates that LEGN has no problem at all paying its short term obligations.
LEGN's Current ratio of 4.62 is in line compared to the rest of the industry. LEGN outperforms 52.11% of its industry peers.
A Quick Ratio of 4.54 indicates that LEGN has no problem at all paying its short term obligations.
LEGN's Quick ratio of 4.54 is in line compared to the rest of the industry. LEGN outperforms 52.64% of its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.54
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.54% over the past year.
LEGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 119.97%.
Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 59.90% on average per year.
EPS 1Y (TTM)65.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)119.97%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%134.73%

3.2 Future

The Earnings Per Share is expected to grow by 31.82% on average over the next years. This is a very strong growth
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.74% on average per year.
EPS Next Y29.62%
EPS Next 2Y52.35%
EPS Next 3Y40.53%
EPS Next 5Y31.82%
Revenue Next Year65.81%
Revenue Next 2Y58.63%
Revenue Next 3Y50.25%
Revenue Next 5Y36.74%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LEGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as LEGN's earnings are expected to grow with 40.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.35%
EPS Next 3Y40.53%

More info and screens

0

5. Dividend

5.1 Amount

LEGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (4/25/2025, 8:20:05 PM)

After market: 34.85 +0.57 (+1.66%)

34.28

+0.04 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners55.57%
Inst Owner Change0.22%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap6.29B
Analysts83.33
Price Target77.99 (127.51%)
Short Float %12.07%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)35.68%
Min EPS beat(2)-52.09%
Max EPS beat(2)123.46%
EPS beat(4)3
Avg EPS beat(4)38.63%
Min EPS beat(4)-52.09%
Max EPS beat(4)123.46%
EPS beat(8)6
Avg EPS beat(8)17.39%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.68%
Min Revenue beat(2)2.2%
Max Revenue beat(2)9.17%
Revenue beat(4)3
Avg Revenue beat(4)4.05%
Min Revenue beat(4)-39.63%
Max Revenue beat(4)44.46%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.7%
PT rev (3m)-6.33%
EPS NQ rev (1m)19.13%
EPS NQ rev (3m)12.72%
EPS NY rev (1m)33.6%
EPS NY rev (3m)-12.68%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.03
P/FCF N/A
P/OCF N/A
P/B 6.04
P/tB 6.06
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS3.42
BVpS5.67
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.6%
ROE -17.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.6%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.38%
Cap/Sales 2.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.54
Altman-Z 7.35
F-Score4
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y29.62%
EPS Next 2Y52.35%
EPS Next 3Y40.53%
EPS Next 5Y31.82%
Revenue 1Y (TTM)119.97%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%134.73%
Revenue Next Year65.81%
Revenue Next 2Y58.63%
Revenue Next 3Y50.25%
Revenue Next 5Y36.74%
EBIT growth 1Y31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.06%
EBIT Next 3Y58.45%
EBIT Next 5Y36.59%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A